SUNNYVALE, Calif., April 12, 2017 /PRNewswire/ -- Renowned radiation oncologists, physicists, therapists and administrators from around the world joined together at the Accuray Exchange in Radiation Oncology (AERO™) Users' Summit to discuss best practices and further collaborations that will improve cancer patients' outcomes and quality of life. The Accuray Incorporated (NASDAQ: ARAY) summit was held April 7 – 8, 2017 at the Hyatt Chicago Magnificent Mile Hotel in Chicago, Illinois.
"The Accuray AERO Users' Summits were established in response to customers' requests for additional peer-to-peer learning opportunities. Our customers have told us that this type of meeting provides them with an invaluable opportunity to share best practices and learn about innovative approaches to improving treatment results for their patients," said Fabienne Hirigoyenberry-Lanson, PhD, Vice President Global Medical and Scientific Affairs, at Accuray.
More than two dozen of the radiation oncology industry's leading clinicians shared information on how to optimize treatment results using the Accuray CyberKnife®, TomoTherapy® and Radixact™ Systems, and PreciseART™ Adaptive Radiation Therapy option. Meeting participants were able to engage in conversations on topics ranging from prostate cancer and nasopharyngeal cancer outcomes, to Iris™ Collimator versus InCise™ Multileaf Collimator in the treatment of liver cancer, and Radixact customer treatment experiences. Additional meeting highlights included:
- Special sessions on the Accuray state of the business and product roadmap
- A keynote address on "The Future of the Affordable Care Act and our U.S. Healthcare Environment"
- Breakout sessions specially created for Administrators and Radiation Therapists
Said Kelly Londy, Executive Vice President, Chief Operating Officer at Accuray, "This summit provided our team with the opportunity to be a part of a unique radiation therapy think tank comprised of some of the most knowledgeable and experienced clinicians in the world. We came together to advance common goals – improving the standard of care for cancer patients and the way radiation therapy is delivered."
About AEROFounded in 2011, AERO was created for CyberKnife System and TomoTherapy System users dedicated to advancing patient care through worldwide clinical and technical partnerships. The AERO community mission is to provide a global forum for the clinical exchange of information between clinicians and physicists for the purpose of setting a new standard in patient care and safety across treatments in the fields of SRS/SBRT, IMRT and conventional radiation therapy. Membership to AERO is free and open to all users of the CyberKnife, TomoTherapy and Radixact Systems.
Accuray is pleased to sponsor the 2017 Accuray pre-ESTRO Planning Workshop for all AERO™ members, to be held at the Hotel Melia in Vienna, Austria on Friday, May 5, 2017, from 12:00pm to 5:00pm. To learn more, visit www.accurayexchange.com.
About the CyberKnife®, TomoTherapy® and Radixact™ SystemsThe Accuray CyberKnife M6™ Series, TomoTherapy H™ Series and Radixact treatment solutions cover the entire spectrum of radiation therapy needs. The CyberKnife M6 Series enables precise, high-quality, dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The CyberKnife System is the only robotic full-body radiosurgery system available today. The TomoTherapy H Series efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures. The Radixact System empowers clinicians by integrating treatment planning, data management and treatment delivery. Using low-dose fan beam megavoltage x-ray radiation, refined beamline and fast imaging technology, the system delivers scalable and highly reliable treatment for patients with a variety of treatment requirements.
Further information on Accuray and the CyberKnife, TomoTherapy and Radixact Systems is available at www.accuray.com.
Important Safety InformationFor Important Safety Information please refer to http://www.accuray.com/safety-statement-radiation-treatment.
About AccurayAccuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 24, 2016, the company's reports on Form 10-Q, filed on November 1, 2016 and February 3, 2017, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Media:Beth KaplanPublic Relations Director, Accuray+1 (408) firstname.lastname@example.org
Jane HauserMSLGROUP+1 (781) email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/accuray-2017-regional-aero-summit-brings-together-leading-oncology-specialists-to-advance-cancer-patient-care-300438442.html
SOURCE Accuray Incorporated